MRNA · 10-Q · 2026Q3 · Full report

Strategic Initiatives

Moderna, Inc. · 2026-11-06 · Importance 26 · Surprise 24

Moderna expects significant future cash outflows for research and development, clinical activities, manufacturing, and commercial infrastructure. The company specifically cites intismeran autogene and other oncology programs, norovirus, new COVID-19 vaccines against SARS-CoV-2 variants, late-stage clinical development, digital capabilities and artificial intelligence, and global commercial, regulatory, sales, marketing, and manufacturing buildout. It says most of these outflows will not be reimbursed or otherwise paid by collaborators or alliances, and that potential milestone and royalty payments may also be owed under collaboration, licensing, and funding arrangements.

Key facts

• The Moderna Science Center lease commenced in the third quarter of 2023 and includes options for two additional seven-year extensions. source
• Moderna intends to use the remaining net proceeds from the 2032 Notes for general corporate purposes, potentially including oncology business growth investments and debt repayment. source
• Moderna had a lease portfolio for facilities and equipment with expirations through 2039. source
• Moderna’s Cambridge Moderna Science Center campus comprises approximately 462,000 square feet and serves as the company headquarters. source